Choosing vaccine targets means tracking what supports each candidate and which failures they share. More candidates or a better computer score do not by themselves show broader, safer tumour recognition.
A neoantigen design board links source alterations, encoded sequence windows, peptide and human leukocyte antigen (HLA) pairs, experimental evidence and unresolved dependencies. It compares a set of candidates for a stated purpose rather than turning one score into proof of a therapeutic target. A source event can generate several peptide windows, so candidate count and independent tumour coverage differ.
The evidence ladder has separate steps. Tumour-normal sequence comparison can support an alteration, and mutant RNA can support a sampled transcript without proving protein production or processing. A processing or binding prediction is a model result. Recovered HLA-associated peptide supports the sampled preparation without settling cell origin, receptor recognition or safety. A controlled T-cell response supports the tested stimulus; controlled recognition or killing of naturally presenting tumour cells tests a more direct function. Tissue distribution, persistence, safety and clinical benefit still need their own evidence. A suitable clinical comparison estimates benefit for that population, product and setting, without automatic transfer elsewhere.
Shares HLA allele names and typing reports, HLA (human leukocyte antigen) and MHC, Neoantigen.
Shares HLA allele names and typing reports, HLA (human leukocyte antigen) and MHC.
Shares Nonsense-mediated RNA decay, Genetic code and reading frame, Personalised neoantigen (mRNA) vaccines.
Shares Nonsense-mediated RNA decay, Genetic code and reading frame.
Shares Antigen-processing machinery (APM), HLA (human leukocyte antigen) and MHC.
Shares Antigen-processing machinery (APM), HLA (human leukocyte antigen) and MHC.
Shares Antigen-processing machinery (APM), HLA (human leukocyte antigen) and MHC.
Shares Antigen-processing machinery (APM), HLA (human leukocyte antigen) and MHC.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/